ERBB2 and breast cancer: Since only patients with an axillary pCR were included in the study of Montagna et al, a skewed distribution of breast cancer subtypes is seen: 54% (619/1144) had HER2+ subtype, 23% (262/1144) had TN subtype and 23% (263/1144) had HR+/HER2− subtype [3].